profit from every $100 of sales.
$0$100
Curanex Pharmaceuticals
$6.20-0.16% today
-50.0% in 1 year
1-year low $3.661-year high $12.40
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Curanex Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $26,000 in 2022 to $0 in 2025, with -$4.23 million of profit last year.
SalesProfit
Curanex Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Curanex Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Curanex Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | – | – | |
| -0 | -0 | -0 | -4 | |
| 0 | -0 | -0 | -4 | |
| -0 | -0 | -0 | -4 | |
| -0.02 | -0.00 | -0.01 | -0.17 | |
| 17.0% | – | – | – | |
| -77.8% | – | – | – | |
| -77.8% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 0 | 1 | 12 |
| Cash | 0 | 0 | 0 | 5 |
| Total debt | – | – | 0 | 0 |
| Total liabilities | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 11 | |
| 42 | 42 | 42 | 25 | |
| -156.2% | -25.4% | -56.7% | -28.8% | |
| -197.7% | -31.9% | -71.8% | -37.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | -0 | -1 | -10 | |
| – | – | – | – | |
| 0 | -0 | -1 | -10 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 1.1×
- 374.0×
- 2,914.6×
- 10,508.8×
- 0.0%
- -0.2%
- 0.0%
Profitability
- 17.0%
- -77.8%
- -77.8%
- 0.0%
- -86.8%
- -46.8%
- -85.4%
- -86.0%
- -88.0%
- –
Growth
- –
- –
- −1,787.1%
- –
- −15.3%
Financial health
- 0.5×
- 0.04
- 3.7%
- 736.4×
- 62.87
- 62.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Bottom 5%of 871
Bottom 41%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 30, 2026 | -0.12 | – | – |
| Nov 14, 2025 | -0.04 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
57No pass
Philip Fisher
42No pass
Peter Lynch
49No pass
Joel Greenblatt
0No pass
Charlie Munger
39No pass
Terry Smith
42No pass
Questions about Curanex Pharmaceuticals
Is Curanex Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Curanex Pharmaceuticals AI analysis
What does Curanex Pharmaceuticals do?
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It is in Biotechnology.
Does Curanex Pharmaceuticals pay a dividend?
No. Curanex Pharmaceuticals does not pay a dividend at the moment.
Is Curanex Pharmaceuticals stock halal?
No. Curanex Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 51% of its market value, at or above the 33% limit. How we check
How has Curanex Pharmaceuticals stock done over the past year?
Down 50.0% over the past twelve months, to $6.20. It traded between $3.66 and $12.40 and is 50.0% below its high.
Who are Curanex Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Curanex Pharmaceuticals's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.